MariSubklewe
@MSubklewe
Followers
846
Following
354
Media
11
Statuses
131
Interests: #AML,#Lymphoma, #Immunotherapy, #BiTE,#CART,#MRD
LMU-University Hospital Munich
Joined August 2020
Prof. @MSubklewe delivered a keynote lecture on mechanisms of action and resistance to bispecifics. She clearly explained key concepts such as antigen loss, T-cell fitness, and the tumor microenvironment -shedding light on challenges and opportunities in the field!
1
7
19
150+ women from all career stages came together at #FAME2025 – Females in Academic Medicine – at @LMU_Muenchen's Medical Faculty. A vibrant, strong space for exchange, inspiration & solidarity. Thanks to @WiebkeArlt, @AnnaFrebel & all who made it possible. #ConnectForChange
0
3
13
New in @BloodJournal: STING activation boosts CD33xCD3 mediated T cell cytotoxicity in #AML by creating an IFN-g- driven feedback loop. Happy to co-lead this with @VeitHornung, and kudos to first authors Andreas Linder & Daniel Nixdorf !
ashpublications.org
Key PointsThe efficacy of AMG 330 against AML cells is greatly enhanced by combining it with a STING agonist.IFN-γ plays a key role in AMG 330–mediated cyt
1
1
15
🚨Hot off the press 🚨 A lesser-known vulnerability in CAR T-cell therapy: Sarcopenia. New in CCR @AACR Predicts ↑ NRM 1/3 patients lose >10% muscle by D30 Linked to fatty acid catabolism With @MichaelDJain @KRejeski @MSubklewe @DrFredLocke
https://t.co/EDNgDAS1QP
pubmed.ncbi.nlm.nih.gov
Skeletal muscle loss after CAR T-cell therapy is common and is associated with fatty acid catabolism. Patients with baseline sarcopenia have poor tolerance and reduced survival. Future studies of...
2
5
25
Don't miss our excellent interview from the #EBMT25 meeting earlier this week in which @MSubklewe of @LMU_Muenchen speaks on the classification & management of hematotoxicity after #CARTCell therapy. Watch here: 👉 https://t.co/NOOQvjv5DE 👈 #ImmunoOnc #HemOnc @TheEBMT
vjhemonc.com
Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Munich, Germany, comments on hematotoxicity post-CAR T-cell therapy, highlighting that it is the most common immune-related adverse...
0
3
10
18 LMU scientists made the "#HighlyCitedResearchers 2024" list published by the analytics company @ClarivateAG, which places them among the most successful in their respective fields. Congratulations on this remarkable achievement! 🎉 #HighlyCited2024
https://t.co/TxWR3Y7mhw
3
7
31
Going beyond Cancer with T cell engagers: First-in-human report on a CD19 TCE for safe & successful treatment in systemic sclerosis. EJC in press. @OncologyAdvance
1
8
33
How does the gut microbiome affect the efficacy of CAR T-cell therapy in patients with hematological malignancies? Prof. @MSubklewe discusses in our podcast. Full episode available below! 👉 https://t.co/iw89R30TKv 👈 #OncTwitter #BloodCancer #HaemOnc
0
2
7
#ESHAL2024 Many thanks to @DombretHerve @Gossenkoppele Christoph Röllig @DrWendyStock for putting together such an exciting program to all faculty for a great meeting & to all participants for the lively interaction! See you next year for #ESHALL2025 & #ESHAML2025
#ESHCONFERENCES
0
1
14
Check out our @EHA_Hematology @TheEBMT consensus guidelines for a new distinct toxicity category of immune effector cell therapy (CAR-T, BsAb): ICAHT! See link above for the accompanying commentary ! Also featured in the @BloodJournal podcast 👇 https://t.co/gEqJBtdPL3
0
8
32
Great to see our @EHA_Hematology and @TheEBMT consensus guidelines article on immune effector cell-associated hematotoxicity out in full print in @BloodJournal ! 🎉🎉🎉 Very proud of this European team effort! https://t.co/uMEuRNphVA
ashpublications.org
Distinct patterns of cytopenias that are distinguishable from standard chemotherapy-associated cytopenias are seen after chimeric antigen receptor T-cell t
2
24
63
Professorinnen @LMU – gemeinsam für die neue Ära der Spitzenmedizin. Female professors @LMU_Uniklinikum - together for the new era of cutting-edge medicine. @LMU_Muenchen; #WomenInMedicine; #WomenInSTEM #femalescientists; #academia; #female; #equality #Diversity
1
13
32
Kudos to the #EHA #EBMT team on putting together #ICAHT consensus guidelines now published in @BloodJournal. Grateful for this incredible European collaboration and a special shoutout to @KRejeski
0
1
20
Real honor to present our consensus grading and best practice recommendations for immune effector cell-associated hematotoxicity (ICAHT) on behalf of @EHA_Hematology and @TheEBMT and entire team today at #EHA23! Manuscript out in parallel @BloodJournal
https://t.co/i5kzAvHiNZ
ashpublications.org
Distinct patterns of cytopenias that are distinguishable from standard chemotherapy-associated cytopenias are seen after chimeric antigen receptor T-cell t
5
30
92
Brilliant Habilitation Presentation by @KRejeski last nite at the LMU medical faculty colloquium. Congrats to this impressive publication track record - honored to be one of his mentors.
2
1
38
RWE of EU & US practice patterns of Immune Effector Cell Associated Hematotoxicity (ICAHT) post #CART. Fantastic collaborative work with @EBMT @EHA and international #CAR community. Check out our survey https://t.co/9K3bHovSDP.
@KRejeski @i_yakoub_agha @ annasureda5
journals.lww.com
n/European Society for Blood and Marrow Transplantation (EHA/EBMT) guidelines on the management of “immune effector cell-associated hematotoxicity” (ICAHT), we undertook a survey of experienced...
0
6
14
Filled with great joy & gratitude for an inspiring networking event of #FAME, a newly founded network of female university professors at the LMU Medical Faculty that fosters female careers and prepares the next generation of female leaders in academic medicine. Many more to come.
2
8
69
Great to participate in this study aiming to identify infection vs CRS after #CART therapy, always a pleasure with @KRejeski @MSubklewe
Can we identify early infections in the setting of CRS after CD19 CAR-T therapy for r/r B-NHL? Check out our new paper addressing this question out today in @Hemasphere_EHA! Tweetorial 👇 https://t.co/mcT2guVKsN
0
2
20
#ISAL2023 | @MSubklewe of @LMU_Muenchen shares some insights into the current status of bispecifics in AML and challenges to overcome. Watch here: 👉 https://t.co/ZLt7avBQrT👈
#AMLsm #LeuSM #ImmunoOnc #HemOnc
vjhemonc.com
Marion Subklewe, MD, Ludwig-Maximilians University, Munich, Germany, shares some insights into the current status of T-cell bispecific antibodies in the treatment of acute myeloid leukemia (AML)....
0
2
6